Skip to main content

NYSE:HCP - HCP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$33.32
▲ +0.24 (0.73%)
Get New HCP Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for HCP in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $33.32.

N/A

The current consensus among 0 investment analysts is to n/a stock in HCP. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $38.00Low
i
Rating by Anthony Paolone at JPMorgan Chase & Co.
10/2/2019BarclaysBoost Price TargetOverweight$37.00 ➝ $39.00Low
i
10/2/2019KeyCorpBoost Price TargetOverweight$34.00 ➝ $37.00Low
i
9/30/2019ScotiabankSet Price TargetBuy$38.00Medium
i
Rating by Nicholas Yulico at Scotiabank
9/17/2019Morgan StanleyBoost Price TargetEqual Weight$32.00 ➝ $35.00High
i
Rating by Vikram Malhorta at Morgan Stanley
9/10/2019JPMorgan Chase & Co.Boost Price TargetNeutral$32.00 ➝ $35.00High
i
9/10/2019ArgusUpgradeHold ➝ BuyHigh
i
9/3/2019BarclaysInitiated CoverageOverweight$37.00High
i
9/3/2019Stifel NicolausBoost Price TargetBuy$34.00 ➝ $37.00High
i
8/1/2019Stifel NicolausBoost Price TargetBuy$32.00 ➝ $34.00Medium
i
7/1/2019KeyCorpBoost Price TargetOverweight$32.00 ➝ $34.00Medium
i
6/13/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$35.00Medium
i
3/28/2019Morgan StanleySet Price TargetHold$32.00Medium
i
Rating by Vikram Malhorta at Morgan Stanley
2/13/2019BMO Capital MarketsReiterated RatingBuy$33.00Low
i
1/9/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$30.00 ➝ $33.00Low
i
1/7/2019Robert W. BairdUpgradeNeutral ➝ OutperformMedium
i
12/10/2018ScotiabankInitiated CoverageOutperform$32.00Medium
i
11/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformMedium
i
11/1/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$29.00 ➝ $30.00Medium
i
Rating by J. France at Cantor Fitzgerald
10/31/2018BMO Capital MarketsReiterated RatingHold$27.00High
i
10/5/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
9/27/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$28.00 ➝ $29.00High
i
Rating by J. France at Cantor Fitzgerald
9/17/2018Bank of AmericaBoost Price TargetBuy$27.50 ➝ $28.00Medium
i
8/16/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$23.50 ➝ $25.00Low
i
8/13/2018MizuhoReiterated RatingBuy$29.00Low
i
Rating by Richard Anderson at Mizuho
8/9/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$24.00 ➝ $26.00Low
i
Rating by Drew Babin at Robert W. Baird
8/7/2018Cantor FitzgeraldInitiated CoverageNeutral$28.00Low
i
8/3/2018Stifel NicolausSet Price TargetBuy ➝ Buy$27.00 ➝ $28.00Low
i
Rating by Chad Vanacore at Stifel Nicolaus
7/24/2018Capital One FinancialInitiated CoverageEqual Weight$27.50Low
i
7/23/2018Capital One FinancialReiterated RatingEqual WeightLow
i
Rating by D. Bernstein at Capital One Financial Co.
6/14/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $23.50Low
i
6/1/2018Raymond JamesReiterated RatingMarket PerformLow
i
Rating by Jonathan Hughes at Raymond James
6/1/2018Evercore ISIDowngradeIn-Line ➝ UnderperformLow
i
5/21/2018Evercore ISIDowngradeIn-Line ➝ Underperform$23.02 ➝ $24.00Low
i
5/21/2018Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
Rating by Jonathan Hughes at Raymond James
5/3/2018BMO Capital MarketsReiterated RatingHold$25.00Low
i
Rating by John Kim at BMO Capital Markets
3/20/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$31.00 ➝ $27.00Low
i
3/8/2018Bank of AmericaUpgradeNeutral ➝ Buy$22.63 ➝ $25.00Low
i
Rating by Juan C. Sanabria at Bank of America Co.
2/23/2018Royal Bank of CanadaReiterated RatingHold$27.00Low
i
2/21/2018UBS GroupReiterated RatingSell ➝ Sell$25.00 ➝ $21.00Medium
i
Rating by Nicholas Yulico at UBS Group AG
2/15/2018Robert W. BairdSet Price TargetHold$24.00Low
i
Rating by Drew Babin at Robert W. Baird
2/15/2018MizuhoSet Price TargetBuy$26.00Low
i
Rating by Richard Anderson at Mizuho
2/14/2018Stifel NicolausReiterated RatingBuy ➝ Buy$29.00 ➝ $27.00High
i
Rating by Chad Vanacore at Stifel Nicolaus
2/13/2018Jefferies Financial GroupReiterated RatingHold$26.00Medium
i
2/13/2018BMO Capital MarketsSet Price TargetHold$25.00Medium
i
Rating by John Kim at BMO Capital Markets
1/15/2018BMO Capital MarketsSet Price TargetHold$25.00Low
i
Rating by John Kim at BMO Capital Markets
1/5/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$29.00 ➝ $26.00Medium
i
12/15/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$29.00Medium
i
12/14/2017Morgan StanleyReiterated RatingEqual Weight$29.00Low
i
12/5/2017Stifel NicolausUpgradeHold ➝ Buy$29.00Low
i
11/7/2017Stifel NicolausLower Price TargetHold ➝ Hold$30.00 ➝ $29.00N/A
i
11/2/2017MizuhoUpgradeNeutral ➝ Buy$32.00N/A
i
10/18/2017BMO Capital MarketsReiterated RatingHold$28.00N/A
i
10/17/2017KeyCorpReiterated RatingHoldN/A
i
10/4/2017Stifel NicolausReiterated RatingHold$30.00Low
i
10/2/2017UBS GroupDowngradeNeutral ➝ Sell$30.00 ➝ $25.00High
i
9/25/2017Morgan StanleyLower Price TargetEqual Weight$31.00 ➝ $29.00Low
i
9/22/2017Bank of AmericaDowngradeBuy ➝ Neutral$33.00 ➝ $31.00High
i
Rating by Juan C. Sanabria at Bank of America Co.
9/17/2017KeyCorpReiterated RatingHoldLow
i
9/6/2017BMO Capital MarketsReiterated RatingHold$32.00Low
i
8/22/2017Stifel NicolausReiterated RatingHold$30.00Medium
i
7/25/2017Jefferies Financial GroupReiterated RatingHold$33.00Low
i
7/24/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral$35.00 ➝ $32.00Medium
i
7/14/2017Stifel NicolausReiterated RatingHold$31.00Medium
i
7/5/2017Royal Bank of CanadaReiterated RatingHold$31.00High
i
6/28/2017MizuhoReiterated RatingNeutralLow
i
6/14/2017Raymond JamesUpgradeUnderperform ➝ Outperform$35.00Low
i
6/14/2017UBS GroupUpgradeUnderperform ➝ OutperformN/A
i
5/12/2017Jefferies Financial GroupReiterated RatingHold$32.00High
i
4/24/2017Evercore ISIDowngradeIn-Line ➝ UnderperformMedium
i
4/21/2017Mitsubishi UFJ Financial GroupInitiated CoverageHold$32.00Low
i
Rating by Karin Ford at Mitsubishi UFJ Financial Group
4/11/2017MizuhoDowngradeBuy ➝ Neutral$34.00 ➝ $32.00Low
i
Rating by Richard Anderson at Mizuho
4/3/2017Bank of AmericaUpgradeNeutral ➝ Buy$33.25 ➝ $35.00Low
i
3/27/2017Evercore ISIUpgradeUnderperform ➝ In-LineLow
i
3/20/2017Morgan StanleyUpgradeUnderweight ➝ Equal Weight$31.00Low
i
3/10/2017Robert W. BairdInitiated CoverageNeutral ➝ Neutral$32.00Low
i
3/3/2017Evercore ISIDowngradeHold ➝ UnderperformN/A
i
2/14/2017BMO Capital MarketsReiterated RatingHold$30.00N/A
i
2/14/2017BarclaysBoost Price TargetEqual Weight$32.00 ➝ $33.00N/A
i
1/25/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$29.00 ➝ $35.00N/A
i
1/5/2017BarclaysReiterated RatingEqual Weight$32.00N/A
i
1/3/2017Royal Bank of CanadaSet Price TargetHold$30.00N/A
i
Rating by Michael A. Carroll at Royal Bank of Canada
12/23/2016MizuhoReiterated RatingBuyN/A
i
Rating by Richard Anderson at Mizuho
12/13/2016BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$29.00 ➝ $30.00N/A
i
Rating by John Kim at BMO Capital Markets
11/21/2016MizuhoUpgradeNeutral ➝ Buy$31.00 ➝ $32.00N/A
i
Rating by Richard Anderson at Mizuho
11/4/2016Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$35.00 ➝ $30.00N/A
i
11/2/2016Stifel NicolausUpgradeSell ➝ Hold$33.00 ➝ $31.00N/A
i
11/2/2016MizuhoLower Price TargetNeutral$37.00 ➝ $31.00N/A
i
Rating by Richard Anderson at Mizuho
11/1/2016BTIG ResearchReiterated RatingNeutralN/A
i
11/1/2016BMO Capital MarketsReiterated RatingSell$33.00N/A
i
Rating by John Kim at BMO Capital Markets
10/4/2016Bank of AmericaUpgradeUnderperform ➝ Neutral$38.50N/A
i
9/18/2016ArgusReiterated RatingHoldN/A
i
Rating by jacob kilstein at Argus
9/4/2016Wells Fargo & CompanyReiterated RatingHoldN/A
i
8/25/2016BTIG ResearchInitiated CoverageNeutralN/A
i
8/24/2016CitigroupBoost Price TargetNeutral$34.00 ➝ $38.00N/A
i
8/23/2016UBS GroupBoost Price TargetNeutral$35.00 ➝ $38.00N/A
i
Rating by Nicholas Yulico at UBS Group AG
8/10/2016MizuhoBoost Price TargetNeutral$32.00 ➝ $37.00N/A
i
Rating by Richard Anderson at Mizuho
7/26/2016Raymond JamesInitiated CoverageUnderperformN/A
i
7/12/2016MizuhoReiterated RatingHold$32.00N/A
i
Rating by Richard Anderson at Mizuho
7/8/2016The Goldman Sachs GroupUpgradeSell ➝ Neutral$26.00 ➝ $36.00N/A
i
Rating by Andrew Rosivach at The Goldman Sachs Group, Inc.
7/6/2016Jefferies Financial GroupReiterated RatingHold ➝ NeutralN/A
i
Rating by Omotayo Okusanya at Jefferies Financial Group Inc.
6/22/2016Morgan StanleyDowngradeEqual Weight ➝ Underweight$32.00N/A
i
6/20/2016BMO Capital MarketsReiterated RatingSellN/A
i
Rating by John Kim at BMO Capital Markets
6/15/2016ArgusReiterated RatingHoldN/A
i
Rating by Jacob Kilstein at Argus
6/1/2016BarclaysDowngradeEqual Weight ➝ Underweight$40.00 ➝ $37.00N/A
i
Rating by Joshua Raskin at Barclays PLC
(Data available from 5/18/2016 forward)
HCP logo
HCP, Inc. is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Read More

Today's Range

Now: $33.32
$33.05
$33.52

50 Day Range

MA: $30.54
$28.42
$35.78

52 Week Range

Now: $33.32
$26.58
$37.93

Volume

2,527,389 shs

Average Volume

3,008,769 shs

Market Capitalization

$16.36 billion

P/E Ratio

18.31

Dividend Yield

4.14%

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of HCP?

The following sell-side analysts have issued stock ratings on HCP in the last year:
View the latest analyst ratings for HCP.

What is the current price target for HCP?

0 Wall Street analysts have set twelve-month price targets for HCP in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for HCP in the next year.
View the latest price targets for HCP.

What is the current consensus analyst rating for HCP?

HCP currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HCP.

What other companies compete with HCP?

How do I contact HCP's investor relations team?

HCP's physical mailing address is 1920 MAIN STREET SUITE 1200, IRVINE CA, 92614. The real estate investment trust's listed phone number is 949-407-0700 and its investor relations email address is [email protected] The official website for HCP is www.hcpi.com.